Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men

Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled phase I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for both studies was the safety and tolerabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro, L, de Hoon, J, Depré, M, Cilissen, C, Miller, J, Gao, W, Panebianco, D, Guo, Z, Troemel, SL, Anderson, MS, Uemura, N, Butterton, J, Wagner, J, Wright, DH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402189/
https://www.ncbi.nlm.nih.gov/pubmed/28796416
http://dx.doi.org/10.1111/cts.12482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402189/
https://www.ncbi.nlm.nih.gov/pubmed/28796416
http://dx.doi.org/10.1111/cts.12482

Ejemplares similares